Martin L. Mai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martin L. Mai has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Hani M. Wadei
Department of Transplant, Mayo Clinic, Jacksonville, FL
3 shared publications C Burcin Taner
2 shared publications- Raymond L. Heilman
Division of Nephrology Mayo Clinic Phoenix Arizona USA
2 shared publications - Amanda E. Kahn
Department of Urology, Mayo Clinic, Jacksonville, USA
1 shared publication - Andrea Lynne Cheville
Department of Physical Medicine and Rehabilitation Mayo Clinic Rochester Minnesota USA
1 shared publication C.B. Taner
1 shared publication
Latest Publications
- Open Access
- 3 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2088
Evaluation of Kidney Function in Cirrhosis: Methods and Pitfalls
Renal dysfunction is highly prevalent among patients with cirrhosis and has major implications for management, prognostication, and liver transplant decision-making. Both acute kidney injury (AKI) and chronic kidney disease (CKD) occur frequently in this population and are driven by a complex interplay of hemodynamic derangements, systemic inflammation, and intrinsic or functional renal injury. Accurate assessment of kidney function is essential, as serum creatinine and estimated glomerular filtration rate (eGFR) calculations directly influence MELD-based transplant allocation, eligibility for simultaneous liver–kidney transplantation (SLKT), and clinical decisions such as drug dosing and peri-transplant immunosuppression strategies. However, creatinine-based assessments are fundamentally limited in cirrhosis due to reduced creatinine production, sarcopenia, expanded volume of distribution, increased tubular secretion, and assay interference from hyperbilirubinemia, resulting in frequent overestimation of true GFR. Alternative methods, including cystatin C-based equations, combined creatinine–cystatin C equations, timed urine clearances, and direct GFR measurement using exogenous filtration markers (iohexol, iothalamate), offer potential advantages but also carry important limitations, particularly in decompensated disease with ascites or inflammation. Newer cirrhosis-specific eGFR equations such as the GRAIL and Royal Free Hospital formulas attempt to address these shortcomings, yet validation studies demonstrate inconsistent accuracy across patient cohorts. This review summarizes the pathophysiologic contributors to renal dysfunction in cirrhosis, evaluates the performance and pitfalls of existing kidney function assessment tools, and highlights the ongoing need for reliable, validated methods tailored to this unique population. Until improved approaches are widely accessible, serum creatinine remains the most practical—albeit imperfect—marker guiding clinical decision-making in cirrhotic patients.
- 3 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2088
Open AccessEvaluation of Kidney Function in Cirrhosis: Methods and Pitfalls
Renal dysfunction is highly prevalent among patients with cirrhosis and has major implications for management, prognostication, and liver transplant decision-making. Both acute kidney injury (AKI) and chronic kidney disease (CKD) occur frequently in this population and are driven by a complex interplay of hemodynamic derangements, systemic inflammation, and intrinsic or functional renal injury. Accurate assessment of kidney function is essential, as serum creatinine and estimated glomerular filtration rate (eGFR) calculations directly influence MELD-based transplant allocation, eligibility for simultaneous liver–kidney transplantation (SLKT), and clinical decisions such as drug dosing and peri-transplant immunosuppression strategies. However, creatinine-based assessments are fundamentally limited in cirrhosis due to reduced creatinine production, sarcopenia, expanded volume of distribution, increased tubular secretion, and assay interference from hyperbilirubinemia, resulting in frequent overestimation of true GFR. Alternative methods, including cystatin C-based equations, combined creatinine–cystatin C equations, timed urine clearances, and direct GFR measurement using exogenous filtration markers (iohexol, iothalamate), offer potential advantages but also carry important limitations, particularly in decompensated disease with ascites or inflammation. Newer cirrhosis-specific eGFR equations such as the GRAIL and Royal Free Hospital formulas attempt to address these shortcomings, yet validation studies demonstrate inconsistent accuracy across patient cohorts. This review summarizes the pathophysiologic contributors to renal dysfunction in cirrhosis, evaluates the performance and pitfalls of existing kidney function assessment tools, and highlights the ongoing need for reliable, validated methods tailored to this unique population. Until improved approaches are widely accessible, serum creatinine remains the most practical—albeit imperfect—marker guiding clinical decision-making in cirrhotic patients.
- Open Access
- 17 August 2020
- Published by Springer Nature in BMC Urology
- Vol. 20 (1) , 1-7
Mayo Adhesive Probability (MAP) score of non-donated kidney aids in predicting post-operative renal function following donor nephrectomy
Background: To examine the association of preoperative Mayo Adhesive Probability (MAP) scores in the donor (MAPd) and non-donor kidneys (MAPnd) with post-donation renal function. Methods: Three hundred thirty-one patients undergoing hand assisted laparoscopic donor nephrectomy (HALDN) were reviewed. MAPd and MAPnd were obtained. Estimated glomerular filtration rate (eGFR) was recorded preoperatively and at 1 day, 1 month, and 6 months postoperatively. Results: Two hundred females and 131 males were evaluated with median BMI 26.4 kg/m2 (range 17.1–39.6) and median age 45 years (range 19–78). MAPd score was 0 for 231 patients (69.8%) and > 0 for 100 patients (30.2%). MAPnd score was 0 for 234 patients (70.7%) and > 0 for 97 patients (29.3%). The median preoperative eGFR was 86.6 ml/min/1.73m2 (range 48.8–138.4). After adjusting for preoperative eGFR, BMI, ASA score, and kidney sidedness, postoperative eGFR was associated with MAP score in the non-donated kidney (p = 0.014) but not in the donated kidney (p = 0.24). Compared to donors with MAPnd = 0, donors with a MAPnd > 0, mean eGFR was − 2.33 ml/min/1.73m2 lower at postoperative day 1 (95% CI − 4.24 to − 0.41, p = 0.018), − 3.02 ml/min/1.73m2 lower at 1 month (95% CI − 5.11 to − 0.93, p = 0.005), and − 2.63 ml/min/1.73m2 lower at 6 months postoperatively (95% CI − 5.01 to − 0.26, p = 0.030). Conclusions: MAP score > 0 in the non-donated kidney is associated with worse renal function in the 6 months following HALDN.
- 17 August 2020
- Published by Springer Nature in BMC Urology
- Vol. 20 (1) , 1-7
Open AccessMayo Adhesive Probability (MAP) score of non-donated kidney aids in predicting post-operative renal function following donor nephrectomy
Background: To examine the association of preoperative Mayo Adhesive Probability (MAP) scores in the donor (MAPd) and non-donor kidneys (MAPnd) with post-donation renal function. Methods: Three hundred thirty-one patients undergoing hand assisted laparoscopic donor nephrectomy (HALDN) were reviewed. MAPd and MAPnd were obtained. Estimated glomerular filtration rate (eGFR) was recorded preoperatively and at 1 day, 1 month, and 6 months postoperatively. Results: Two hundred females and 131 males were evaluated with median BMI 26.4 kg/m2 (range 17.1–39.6) and median age 45 years (range 19–78). MAPd score was 0 for 231 patients (69.8%) and > 0 for 100 patients (30.2%). MAPnd score was 0 for 234 patients (70.7%) and > 0 for 97 patients (29.3%). The median preoperative eGFR was 86.6 ml/min/1.73m2 (range 48.8–138.4). After adjusting for preoperative eGFR, BMI, ASA score, and kidney sidedness, postoperative eGFR was associated with MAP score in the non-donated kidney (p = 0.014) but not in the donated kidney (p = 0.24). Compared to donors with MAPnd = 0, donors with a MAPnd > 0, mean eGFR was − 2.33 ml/min/1.73m2 lower at postoperative day 1 (95% CI − 4.24 to − 0.41, p = 0.018), − 3.02 ml/min/1.73m2 lower at 1 month (95% CI − 5.11 to − 0.93, p = 0.005), and − 2.63 ml/min/1.73m2 lower at 6 months postoperatively (95% CI − 5.01 to − 0.26, p = 0.030). Conclusions: MAP score > 0 in the non-donated kidney is associated with worse renal function in the 6 months following HALDN.
- Open Access
- 30 January 2019
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 3 (1) , 1-9
Patient experience after kidney transplant: a conceptual framework of treatment burden
Kidney transplant recipients face a lifelong regimen of medications, health monitoring and medical appointments. This work involved in managing one’s health and its impact on well-being are referred to as treatment burden. Excessive treatment burden can adversely impact adherence and quality of life. The aim of this study was to develop a conceptual framework of treatment burden after kidney transplantation. Qualitative interviews were conducted with kidney transplant recipients (n = 27) from three Mayo Clinic transplant centers. A semi-structured interview guide originally developed in patients with chronic conditions and tailored to the context of kidney transplantation was utilized. Themes of treatment burden after kidney transplantation were confirmed in two focus groups (n = 16). Analyses confirmed three main themes of treatment burden after kidney transplantation: 1) work patients must do to care for their health (e.g., attending medical appointments, taking medications), 2) challenges/stressors that exacerbate felt burden (e.g., financial concerns, health system obstacles) 3) impacts of burden (e.g., role/social activity limitations). Patients describe a significant amount of work involved in caring for their kidney transplants. This work is exacerbated by individual, interpersonal and system-related factors. The framework will be used as a foundation for a patient-reported measure of treatment burden to promote better care after kidney transplantation.
- 30 January 2019
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 3 (1) , 1-9
Open AccessPatient experience after kidney transplant: a conceptual framework of treatment burden
Kidney transplant recipients face a lifelong regimen of medications, health monitoring and medical appointments. This work involved in managing one’s health and its impact on well-being are referred to as treatment burden. Excessive treatment burden can adversely impact adherence and quality of life. The aim of this study was to develop a conceptual framework of treatment burden after kidney transplantation. Qualitative interviews were conducted with kidney transplant recipients (n = 27) from three Mayo Clinic transplant centers. A semi-structured interview guide originally developed in patients with chronic conditions and tailored to the context of kidney transplantation was utilized. Themes of treatment burden after kidney transplantation were confirmed in two focus groups (n = 16). Analyses confirmed three main themes of treatment burden after kidney transplantation: 1) work patients must do to care for their health (e.g., attending medical appointments, taking medications), 2) challenges/stressors that exacerbate felt burden (e.g., financial concerns, health system obstacles) 3) impacts of burden (e.g., role/social activity limitations). Patients describe a significant amount of work involved in caring for their kidney transplants. This work is exacerbated by individual, interpersonal and system-related factors. The framework will be used as a foundation for a patient-reported measure of treatment burden to promote better care after kidney transplantation.
- 1 January 2013
- p. 235-9
Desensitization in the era of kidney paired donation: the Mayo Foundation 3-site experience.
Sensitized renal allograft candidates face significant barriers to transplantation. While several options exist, including: kidney paired donation (KPD), desensitization, or pursuing a deceased donor kidney transplant, it is unclear from existing data what is the appropriate protocol for an individual patient. In this study, we seek to devise a balance between waiting for a paired donor and combining desensitization with KPD.
- 1 January 2013
- p. 235-9
Desensitization in the era of kidney paired donation: the Mayo Foundation 3-site experience.
Sensitized renal allograft candidates face significant barriers to transplantation. While several options exist, including: kidney paired donation (KPD), desensitization, or pursuing a deceased donor kidney transplant, it is unclear from existing data what is the appropriate protocol for an individual patient. In this study, we seek to devise a balance between waiting for a paired donor and combining desensitization with KPD.
- 27 January 2009
- Published by Wolters Kluwer Health in Transplantation
- Vol. 87 (2) , 227-232
Excellent Renal Allograft Survival in Donor-Specific Antibody Positive Transplant Patients—Role of Intravenous Immunoglobulin and Rabbit Antithymocyte Globulin
Timely transplantation of sensitized kidney recipients remains a challenge. Patients with a complement-dependent cytotoxicity negative and flow cytometry (FC) positive crossmatch carry increased risk of antibody-mediated rejection and thus graft loss. Solid phase assays are available to confirm donor specificity for antibody identified by FC crossmatch. Treatment using induction therapy with rabbit antithymocyte globulin (RATG) and intravenous immunoglobulin (IVIG) may allow successful transplant of these high-risk patients. A retrospective study of 264 consecutive patients after exclusions yielded 94 complement-dependent cytotoxicity anti-human globulin crossmatch-negative patients, including group 1: 58 primary transplants with panel-reactive antibody (PRA) less than 20%, group 2: 16 retransplants and PRA more than 20% who were FC crossmatch-negative, and group 3: 20 retransplants and PRA more than 20% who were FC crossmatch-positive. All were treated with RATG induction and maintenance therapy with tacrolimus, mycophenolate mofetil, and corticosteroids. Only group 3 received IVIG at 500 mg/kg daily in three doses. Eighteen of 20 patients in group 3 had donor-specific antibody identified by solid phase assay. Cellular- and antibody-mediated rejections were statistically higher in group 3. Two-year serum creatinine and glomerular filtration rate along with 3-year patient and graft survival were comparable between the groups. Sensitized patients with positive FC crossmatch and donor-specific antibody identified by solid phase assays can be successfully transplanted using standard RATG induction, IVIG, and maintenance immunosuppression with equal renal function and graft survival to immunologically lower risk recipients. Given these results, this patient group should not be excluded from transplantation based on antibody specificities determined by virtual crossmatch techniques.
- 27 January 2009
- Published by Wolters Kluwer Health in Transplantation
- Vol. 87 (2) , 227-232
Excellent Renal Allograft Survival in Donor-Specific Antibody Positive Transplant Patients—Role of Intravenous Immunoglobulin and Rabbit Antithymocyte Globulin
Timely transplantation of sensitized kidney recipients remains a challenge. Patients with a complement-dependent cytotoxicity negative and flow cytometry (FC) positive crossmatch carry increased risk of antibody-mediated rejection and thus graft loss. Solid phase assays are available to confirm donor specificity for antibody identified by FC crossmatch. Treatment using induction therapy with rabbit antithymocyte globulin (RATG) and intravenous immunoglobulin (IVIG) may allow successful transplant of these high-risk patients. A retrospective study of 264 consecutive patients after exclusions yielded 94 complement-dependent cytotoxicity anti-human globulin crossmatch-negative patients, including group 1: 58 primary transplants with panel-reactive antibody (PRA) less than 20%, group 2: 16 retransplants and PRA more than 20% who were FC crossmatch-negative, and group 3: 20 retransplants and PRA more than 20% who were FC crossmatch-positive. All were treated with RATG induction and maintenance therapy with tacrolimus, mycophenolate mofetil, and corticosteroids. Only group 3 received IVIG at 500 mg/kg daily in three doses. Eighteen of 20 patients in group 3 had donor-specific antibody identified by solid phase assay. Cellular- and antibody-mediated rejections were statistically higher in group 3. Two-year serum creatinine and glomerular filtration rate along with 3-year patient and graft survival were comparable between the groups. Sensitized patients with positive FC crossmatch and donor-specific antibody identified by solid phase assays can be successfully transplanted using standard RATG induction, IVIG, and maintenance immunosuppression with equal renal function and graft survival to immunologically lower risk recipients. Given these results, this patient group should not be excluded from transplantation based on antibody specificities determined by virtual crossmatch techniques.
- 1 June 2004
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 9 (2) , 116-122
Renal dysfunction and orthotopic liver transplantation
Purpose of review Transplant clinicians must deal with renal dysfunction in patients waiting for liver transplant and in the patient after transplant. The purpose of this review is to examine new advances in the treatment of renal dysfunction before transplant, the indications and outcomes for combined liver kidney transplant, and recent advances in treating the renal dysfunction that occurs after liver transplant as a consequence of treatment with immunosuppressive drugs. Recent findings New strategies for the treatment of renal dysfunction including hepatorenal syndrome that occurs before liver transplant have been described. These include albumin, terlipressin, transjugular intrahepatic portosystemic shunts, and albumin dialysis. Results of combined liver kidney transplant have been reviewed using the UNOS database and confirm that the procedure is viable but limited by decreased patient survival compared with patients receiving kidney transplant alone. It has also been confirmed that there is less renal rejection in the combined transplants. Finally, strategies using calcineurin minimization, mycophenolate mofetil, and sirolimus have addressed the growing problem with long-term nephrotoxicity secondary to calcineurin inhibitors. It has been recognized that as many as 12% of long-term liver transplant survivors develop end-stage renal disease. Summary Renal dysfunction is a growing problem in patients awaiting liver transplant. New strategies have been developed to deal with this problem. Combined liver/kidney transplant is a viable option for the patient with combined end-organ damage. There is growing concern over the long-term consequence of chronic calcineurin inhibitor therapy for chronic kidney disease and end-stage renal disease. Multiple new strategies to deal with this have been proposed. They have had variable success, and further research is needed.
- 1 June 2004
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 9 (2) , 116-122
Renal dysfunction and orthotopic liver transplantation
Purpose of review Transplant clinicians must deal with renal dysfunction in patients waiting for liver transplant and in the patient after transplant. The purpose of this review is to examine new advances in the treatment of renal dysfunction before transplant, the indications and outcomes for combined liver kidney transplant, and recent advances in treating the renal dysfunction that occurs after liver transplant as a consequence of treatment with immunosuppressive drugs. Recent findings New strategies for the treatment of renal dysfunction including hepatorenal syndrome that occurs before liver transplant have been described. These include albumin, terlipressin, transjugular intrahepatic portosystemic shunts, and albumin dialysis. Results of combined liver kidney transplant have been reviewed using the UNOS database and confirm that the procedure is viable but limited by decreased patient survival compared with patients receiving kidney transplant alone. It has also been confirmed that there is less renal rejection in the combined transplants. Finally, strategies using calcineurin minimization, mycophenolate mofetil, and sirolimus have addressed the growing problem with long-term nephrotoxicity secondary to calcineurin inhibitors. It has been recognized that as many as 12% of long-term liver transplant survivors develop end-stage renal disease. Summary Renal dysfunction is a growing problem in patients awaiting liver transplant. New strategies have been developed to deal with this problem. Combined liver/kidney transplant is a viable option for the patient with combined end-organ damage. There is growing concern over the long-term consequence of chronic calcineurin inhibitor therapy for chronic kidney disease and end-stage renal disease. Multiple new strategies to deal with this have been proposed. They have had variable success, and further research is needed.